Aardvark Therapeutics Halts All Lead Clinical Trials Due to Cardiac Safety Concerns, Delays Key Data

summarizeSummary

Aardvark Therapeutics has voluntarily paused its Phase 3 HERO trial for ARD-101 and Phase 2 trials for ARD-201 due to reversible cardiac observations in a healthy volunteer study, significantly delaying its development timeline and raising substantial uncertainty about its lead programs.

check_boxKey Events

• Clinical Trial Halt

  Voluntary pause of Phase 3 HERO and OLE trials for ARD-101 (Prader-Willi Syndrome) and Phase 2 POWER and STRENGTH trials for ARD-201 (obesity) on February 27, 2026, due to reversible cardiac observations in a healthy volunteer study.

• Development Timeline Delayed

  Topline data for the HERO trial, previously anticipated in Q3 2026, is now delayed, with further guidance expected in Q2 2026. This impacts the entire lead pipeline.

• Financial Performance

  Reported a net loss of $57.6 million for 2025, significantly higher than $20.6 million in 2024, with an accumulated deficit of $115.9 million.

• Cash Runway

  Existing cash, cash equivalents, and short-term investments of $110.0 million as of December 31, 2025, are projected to fund operations into Q2 2027, but this estimate is subject to change based on the outcome of clinical program evaluations.

auto_awesomeAnalysis

This 10-K filing confirms the critical setback for Aardvark Therapeutics, detailing the voluntary pause of its lead clinical programs, ARD-101 (Phase 3 for Prader-Willi Syndrome) and ARD-201 (Phase 2 for obesity), following reversible cardiac observations in a healthy volunteer study. This event, previously announced via an 8-K and news, is a severe blow to a clinical-stage biotech whose valuation is heavily tied to its pipeline success. The company's cash runway into Q2 2027, while not immediately critical, becomes more precarious given the increased R&D expenses and the need for substantial additional funding to navigate these clinical delays and potential protocol revisions. The market has already reacted to the initial news, with the stock trading near its 52-week low, but the comprehensive details in this annual report underscore the significant uncertainty and risk to the company's future. Investors should monitor the Q2 2026 guidance for clarity on the path forward.